Latest News

 Filter by Provider

Intuit took steps to embrace AI.

The bank's willingness to sacrifice market share for loan pricing power signals how disciplined management can sustain profitability across rate cycles.

Brookfield Infrastructure's growing cash earnings support its payout, with financing costs setting the pace of the next increase.

A rival chipmaker is buying a big laser maker. Is the AI chip giant's stock, around 30% under its record, still worth buying?

Gross margin climbed to 22.5% in the first half, and management expects further gains, pointing to better profit quality beyond sheer deal volume.

Investors were clearly impressed by the gaming company's third-quarter performance.

See why Canadian Natural Resources and CN Rail deserve a spot in a buy and hold dividend portfolio built to last for years.

The education company's patience is paying off.

Is the AI boom running out of steam, or is the market simply taking a breather?

Telus and BCE now offer similar starting yields, making payout coverage and recovery demands the more useful comparison.

ARM (NASDAQ:ARM) reported record second-quarter fiscal 2027 revenue as licensing demand and data center royalties grew, while executives said they had greater confidence in the sales potential of the company’s forthcoming Arm AGI CPU. Revenue rose 27% year over year to $1.44 billion, marking Arm’s

GRAIL (NASDAQ:GRAL) reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri cancer screening test by early in the first quarter of 2027. The company reported revenue of $37.

electroCore (NASDAQ:ECOR) reported record third-quarter sales and a narrower loss, but revised its 2026 revenue outlook as changes to its sales organization took longer than expected to reach the full field. The medical device company reported revenue of $9.7 million for the quarter ended Sept. 30,

Caris Life Sciences (NASDAQ:CAI) raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company also reported lower quarterly profit as it increased spending on its sales force, marketing and new

Amplitude (NASDAQ:AMPL) reported third-quarter revenue of $111 million, up 25% from a year earlier, and raised its full-year outlook as enterprise customers adopted more of its analytics and experimentation products. The company recorded non-GAAP operating income of $5.7 million, its highest quarte

Barrett Business Services (NASDAQ:BBSI) reported higher third-quarter gross billings but lower earnings per share as new client additions were offset by workforce reductions among existing customers and smaller favorable workers’ compensation adjustments. The company lowered its full-year outlook f

Expedia Group (NASDAQ:EXPE) raised its full-year 2026 outlook after third-quarter bookings and revenue grew by double digits, though executives expect growth to moderate in the fourth quarter as travel disruptions, tougher comparisons and the timing of a promotion weigh on results. Gross bookings r

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson’s disease psychosis drug NUPLAZID drove growth. The company raised its full-year DAYBUE sales out

Clover Health Investments (NASDAQ:CLOV) raised the lower end of its 2026 financial guidance after reporting a third-quarter profit, and said it expects to achieve its first full year of GAAP net income profitability. The Medicare Advantage insurer reported third-quarter revenue of $759 million, up

Beyond Meat (NASDAQ:BYND) reported a narrower third-quarter loss and its highest gross margin in five years, but revenue continued to fall as weaker U.S. demand and lower international food-service sales outweighed growth in international retail. The plant-based food company reported revenue of $64

The niche financial services company delivered an estimates-crushing third quarter.

Tamarack Valley plans a 20% dividend boost tied to its $10 billion Headwater merger. See what free cash flow, dividend safety, and risks mean for income investors.

Competitor consolidation in New England is creating share-gain opportunities that management plans to seize with local decision-making.

These AI stocks have serious room for growth.

Premium product adoption is lifting margins faster than revenue growth, a sign of pricing power in a competitive market.

Cricut's third-quarter gross margin was flattered by one-off IEEPA tariff refunds and inventory gains, so the promotional pricing ahead may reveal how much of that strength holds.

Lam Research is a semiconductor machine business that’s breaking records, but its stock price has been cut nearly in half from highs in 2026. Is it a good stock to buy right now?

Operating margins are expected to reach the high end of management's long-term range despite component disruptions and rising costs.

Dealer channel relief and a China plant feeding non-U.S. markets could reshape XPEL's margins, but both depend on a 2027 rollout.

IonQ's stock has had a rough year, but a turnaround could be coming.

Arcutis Biotherapeutics (NASDAQ:ARQT) raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand. The company reported $143.9 million in third-quarter net product revenue, up 11% f

Enerpac Tool Group (NYSE:EPAC) outlined a plan to grow organic revenue faster than its markets through fiscal 2030, while integrating its newly acquired SFE fabrication tools business and expanding profit margins. At its 2026 Investor Day, the company introduced a growth strategy called PROPEL and

Cirrus Logic (NASDAQ:CRUS) reported fiscal second-quarter revenue of $559.5 million, up 22% from the prior quarter, as higher smartphone volumes and increased content per device helped offset weaker PC and general-market sales. The chipmaker forecast revenue of $510 million to $570 million for the

AppLovin (NASDAQ:APP) reported record third-quarter 2026 revenue of $2.18 billion, up 55% from a year earlier, as improvements to its advertising models helped drive growth in mobile gaming and consumer advertising. Both revenue and adjusted EBITDA exceeded the high end of the company’s guidance. C

Billiontoone (NASDAQ:BLLN) raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics company also reported its fifth consecutive quarter of positive GAAP operating income. Revenue fo

Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development. The company reported total revenue of

ARKO Petroleum reported higher third-quarter earnings and raised its full-year adjusted EBITDA outlook, as stronger fuel margins offset lower sales volumes and the company worked toward closing an acquisition in the fourth quarter. Net income rose to $13.3 million from $10.1 million a year earlier.

Alto Ingredients (NASDAQ:ALTO) reported a fifth consecutive quarter of positive gross profit, operating income, net income and adjusted EBITDA, while raising its expectations for 2026 clean fuel tax credit earnings. On its Nov. 4 earnings call, the producer of specialty alcohols, renewable fuel and